Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome (RASTAT)

children with Noonan syndrome. Half of patients will receive simvastatin while the other half will receive a placebo.

  • 29 views
  • 24 Feb, 2022
  • 9 locations
Lipid Management in Renal Transplant Recipients Using Evolocumab.

), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor), and pitavastatin (Livalo). These drugs have been proven to lower lipid levels as well as cardiovascular risk. However, statin-based drugs

cholesterol level
pravastatin
lovastatin
cardiovascular disease
hmg-coa reductase inhibitors
  • 0 views
  • 22 Jul, 2022
  • 1 location
Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.

intravascular ultrasound
stenosis
rosuvastatin
heart disease
ezetimibe
  • 10 views
  • 18 Nov, 2021
  • 1 location
DLBS1033 for Acute Ischemic Stroke Patients (ADDLIST)

This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients. It is hypothesized that the improvement in functional outcomes as measured by NIHSS and BI as well as the …

  • 85 views
  • 21 Mar, 2022
  • 3 locations
Investigation of the Gut Microbiome and Statin Response (INGEST)

There is evidence that the bacteria that naturally reside in the gut can influence how well we respond to medications. Therefore this study will look at how rosuvastatin, a medication used to lower cholesterol levels, may change the bacteria in the gut. Investigators will also examine how the gut bacteria …

Accepts healthy volunteers
  • 115 views
  • 29 May, 2022
  • 1 location
Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis (STATLiver)

In a randomized, doubleblind and placebo-controlled trial we assess both clinical and cellular effects of atorvastatin in patients with liver cirrhosis. 162 participants will be allocated to atorvastatin 10-20 mg or placebo for 18 months. Clinical outcomes of survival, hospitalizations and safety will be evaluated. Also, the trial will investigate …

hepatic venous pressure gradient
hypertension
venous pressure
biopsy of liver
  • 0 views
  • 20 Feb, 2022
  • 1 location
Ezetimibe Utilization Early After Acute Myocardial Infarction "EzAMI Trial"

Rationale Patients with acute coronary syndromes are at an increased risk for recurrent adverse coronary events, particularly during the early period following their initial presentation. Early (in-hospital) initiation of high-intensity statins reduces the risk of recurrent events and is therefore recommended by the best current practice guidelines.(1,2) However, the delayed …

evolocumab
ezetimibe
hmg-coa reductase inhibitors
myocardial infarction
statin therapy
  • 0 views
  • 06 Aug, 2021
  • 1 location
Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery (finnptx)

Chronic lower limb ischemia due to atherosclerosis causes significant morbidity especially in elderly: the prevalence of asymptomatic obstructive peripheral atherosclerosis among 40-74 old is 4-22%. The prevalence of its milder symptomatic manifestation, intermittent claudication among 40 years old men is about 1% and among 70 years old it is 7%. …

limb ischemia
atherosclerosis
balloon angioplasty
ischemia
paclitaxel
  • 33 views
  • 06 Jun, 2022
  • 1 location
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) (EPIC-HIV)

Atherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future CV events in the general population. PCSK9 has emerged as an important pharmacologic target …

cholesterol level
angiography
hmg-coa reductase inhibitors
hypertension
peripheral vascular disease
  • 17 views
  • 09 May, 2022
  • 1 location
An Analysis to Assess Non-adherence in People With Type 2 Diabetes

Non-adherence is defined as: "the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider". Non-adherence in chronic cardiometabolic diseases including diabetes is very common and is often the primary reason for treatment failure. This …

diabetes
  • 1 views
  • 29 May, 2022
  • 2 locations